# Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

> **NCT01757639** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 42 (actual)

## Conditions studied

- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- Chronic Myelomonocytic Leukemia
- Myelodysplastic Syndrome
- Previously Treated Myelodysplastic Syndrome
- Recurrent Adult Acute Myeloid Leukemia
- Secondary Myelodysplastic Syndrome

## Interventions

- **BIOLOGICAL:** Ipilimumab
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT01757639
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-14
- **Primary completion:** 2016-12-31
- **Final completion:** —
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2018-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01757639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01757639, "Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT01757639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*